drugset / Trial / NCT01586052

Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1

NCT01586052

Phase 1 Completed 11 enrolled MinYoung Kim, M.D. LG Life Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

This purpose of this phase 1 study is to investigate the safety and efficacy of erythropoetin for children with cerebral palsy.

Timeline

Start
2012-06
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 250 iu/kg Other

Indications